At present, blenrep (belantamab mafodotin-blmf), a BCMA-targeted ADC drug, has been approved for the treatment of highly refractory MM (Table 2) [20, 33, 34]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.